All In Biotech

Drug Trial Radar · NCT05248867

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines

Last checked: Nov 20, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 638 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

638

Actual

Start

Mar 16, 2022

Primary completion

Mar 17, 2023

Study completion Mar 17, 2023

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study was to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in participants with moderate to severe GL. This was a 12-week study in which eligible subjects were enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants were randomly assigned to receive AGN-151586 or placebo. There was 1 in a 4 chance that participants would receive placebo. Around 600 adult participants with moderate to severe GL were to be enrolled in the study in approximately 38 sites across the world. Participants received either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may have received an open-label treatment of AGN-151586 during the study. Participants attended regular visits during the study at a study site. The effect of the treatment was checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.

Conditions

  • Glabellar Lines

Interventions

  • PlaceboDrug

    Placebo solution for injection

  • AGN-151586Drug

    AGN-151586 solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]Time frame: Baseline, Day 7 (Double-blind period)
  2. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]Time frame: Baseline, Day 7 (Double-blind period)
  3. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]Time frame: Baseline, Day 7 (Double-blind Period)
  4. Number of Participants With Adverse EventsTime frame: From time of informed consent to end of study; median time on follow-up was 85 days for Double-blind Placebo, AGN-151586, Open-label Placebo/AGN-151586 and AGN-151586/AGN-151586 groups, 50 days for Placebo/None group, and 53 days for AGN-151586/None group

Locations

38 sites in 5 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Derm Ctr /ID# 232378

    Birmingham, Alabama

  • Clinical Testing of Beverly Hills /ID# 233195

    Encino, California

  • Westside Aesthetics /ID# 232443

    Los Angeles, California

  • The Research Center at The Maas Clinic /ID# 241262

    San Francisco, California

  • Center for Dermatology and Dermatologic Surgery /ID# 232315

    Washington D.C., District of Columbia

  • Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232439

    Boca Raton, Florida

  • Dermatology Clinic & Cosmetic Center /ID# 244295

    Baton Rouge, Louisiana

  • Delricht Research /ID# 241253

    New Orleans, Louisiana

  • Skincare Physicians /ID# 233938

    Chestnut Hill, Massachusetts

  • BOYD Beauty Birmingham /ID# 232383

    Birmingham, Michigan

  • Skin Search of Rochester Inc. /ID# 232549

    Rochester, New York

  • Aesthetic Solutions /ID# 232389

    Chapel Hill, North Carolina

  • Aventiv Research Dublin /ID# 233936

    Dublin, Ohio

  • KGL Skin Study Center, LLC /ID# 233549

    Newtown Square, Pennsylvania

  • Nashville Center for Laser and Facial Surgery /ID# 242535

    Nashville, Tennessee

  • Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 232410

    Austin, Texas

  • Dallas Plastic Surgery Institute /ID# 232328

    Dallas, Texas

  • Austin Institute for Clinical Research at SBA Dermatology /ID# 232316

    Houston, Texas

  • Beacon Dermatology Inc /ID# 233227

    Calgary, Alberta, Canada

  • Alberta DermaSurgery Centre /ID# 241172

    Edmonton, Alberta, Canada

  • Dr. Wei Jing Loo Medicine Prof /ID# 241863

    London, Ontario, Canada

  • Erevna Innovations Inc. /ID# 239592

    Westmount, Quebec, Canada

  • Noahklinik GmbH /ID# 241184

    Kassel, Germany

  • Hautok and Hautok-cosmetics /ID# 232393

    München, Germany

  • Privatpraxis fuer Dermatologie und Aesthetik /ID# 241544

    München, Germany

  • MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 241186

    Oberursel, Germany

  • Studienzentrum Theatiner46 /ID# 241185

    Munich, Bavaria, Germany

  • Rosenpark Research /ID# 232391

    Darmstadt, Hesse, Germany

  • Privatpraxis Dr. Hilton & Partner /ID# 232392

    Düsseldorf, North Rhine-Westphalia, Germany

  • Derma-B Egeszsegugyi es Szolgaltato Kft. /ID# 244706

    Debrecen, Hungary

  • Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 244707

    Pécs, Hungary

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 244708

    Szeged, Csongrád megye, Hungary

  • Derm-Surg Kft. /ID# 244709

    Kaposvár, Somogy County, Hungary

  • Instytut Zdrowia Dr Boczarska-Jedynak Sp. Z O.O. Sp.K. /Id# 242990

    Oświęcim, Lesser Poland Voivodeship, Poland

  • Dermed Centrum Medyczne Sp. z o.o /ID# 242972

    Lodz, Łódź Voivodeship, Poland

  • Clinical Research Group Sp. z o.o. /ID# 242988

    Warsaw, Masovian Voivodeship, Poland

  • High-Med Przychodnia Specjalistyczna /ID# 242973

    Warsaw, Masovian Voivodeship, Poland

  • Novo-Med Zielinski i Wspolnicy Spolka Jawna /ID# 242986

    Katowice, Silesian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.